Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Soligenix Inc (NQ: SNGX )

1.310 USD -0.080 (-5.76%)
Official Closing Price Updated: 7:54 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 926,300
Open 1.370
Bid (Size) 1.300 (2)
Ask (Size) 1.320 (40)
Prev. Close 1.390
Today's Range 1.285 - 1.380
52wk Range 1.210 - 2.990
Shares Outstanding 40,020,461
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Soligenix Announces Presentations at Prominent Scientific Conferences
Key Data Outcomes Presented for HyBryte™ and CiVax™ 
From PR Newswire
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet... 
From PR Newswire

Performance

YTD
-2.96%
-2.96%
1 Month
-25.14%
-25.14%
3 Month
-21.56%
-21.56%
6 Month
-23.84%
-23.84%
1 Year
-10.27%
-10.27%

More News

Read More
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
From PR Newswire
Soligenix Anticipated to Achieve Multiple Milestones in 2021
From Newsfile Corp News Releases
Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
From PR Newswire
Looking For The Best Penny Stocks To Watch? 3 To Know Right Now
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
From PR Newswire
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
From PR Newswire
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
From NewMediaWire
Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track
From Newsfile Corp News Releases
Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.